Risuteganib: Research & Studies

Research Overview#

Risuteganib has a growing evidence base supporting its potential as a first-in-class treatment for intermediate dry AMD. The clinical program includes a completed Phase 2a proof-of-concept trial with statistically significant visual acuity improvements and a Phase 2b/3 trial with FDA Special Protocol Assessment agreement.

Phase 2a Trial: Boyer et al. (PMID 34185587)#

The pivotal Phase 2a study was a prospective, randomized, double-masked, sham-controlled, multicenter US trial enrolling 40 patients with intermediate dry AMD and BCVA between 20/40 and 20/200.

Study Design#

• Patients randomized to intravitreal 1.0 mg risuteganib or sham injection
• Risuteganib group received a second injection at week 16
• Sham group crossed over to risuteganib at week 16
• Primary endpoint assessed at week 28 (risuteganib) and week 12 (sham)

Key Results#

The primary endpoint was met with statistical significance:

These results are particularly noteworthy because improvement in visual acuity is unexpected in dry AMD, a disease typically characterized by progressive vision loss. No existing treatment has demonstrated visual acuity improvement in intermediate dry AMD.

Safety#

No drug-related serious adverse events were reported. The only treatment-related adverse event was vitreous floaters, which resolved spontaneously.

OCT Biomarker Analysis#

A subsequent analysis (PMID 35569763) examined baseline OCT features that predicted treatment response, finding that patients with preserved outer retinal integrity showed the greatest benefit from risuteganib treatment. This finding may help identify optimal candidates for risuteganib therapy.

Phase 2b/3 Trial Design#

Allegro Ophthalmics received FDA agreement under Special Protocol Assessment for the Phase 2b/3 trial design:

• 5 intravitreal injections, 12 weeks apart
• Primary endpoint: BCVA improvement at 52 weeks
• Continued treatment during the follow-up safety period
• AffaMed Therapeutics received CTA approval for a parallel trial in mainland China

Evidence Quality Assessment#

Research Evidence Context#

Risuteganib belongs to the Healing category of research peptides. The research evidence for Risuteganib spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Risuteganib:

Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial#

Authors: Boyer DS, Gonzalez VH, Kunimoto DY, et al. (2021) — Ophthalmic Surgery, Lasers and Imaging Retina

Phase 2a prospective, double-masked, sham-controlled, multicenter trial evaluating intravitreal 1.0 mg risuteganib in patients with intermediate dry AMD and BCVA between 20/40 and 20/200.

Key Findings:

• 48% of risuteganib patients gained 8 or more ETDRS letters at week 28 versus 7% sham at week 12 (p=0.013)
• 20% of risuteganib patients gained 15 or more letters at week 28 versus 0% sham
• No drug-related serious adverse events reported
• Only treatment-related adverse event was vitreous floaters (spontaneously resolved)

Limitations: Small sample size (40 patients randomized). Sham group crossed over to risuteganib at week 16, limiting long-term placebo comparison. Short observation period.

Risuteganib - a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema#

Authors: Shaw LT, Mackin A, Shah R, et al. (2020) — Expert Opinion on Investigational Drugs

Expert review of risuteganib covering its mechanism of action targeting multiple integrin heterodimers, preclinical data, and clinical trial results in dry AMD and DME.

Key Findings:

• Risuteganib targets four integrin heterodimers (alphaVbeta3, alphaVbeta5, alpha5beta1, alphaMbeta2)
• Preclinical studies showed VEGF-independent anti-angiogenic activity
• Improved Mueller cell viability and mitochondrial health in preclinical models
• Favorable safety profile across clinical trials

Limitations: Review article based on early-phase clinical data. Limited long-term efficacy and safety data available at time of publication.

Evidence Quality Assessment#

The overall evidence level for Risuteganib is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Risuteganib have been identified:

• Phase 2b/3 confirmation trial results (FDA SPA agreed, study ongoing)
• Long-term efficacy and safety data beyond 28 weeks
• Optimal dosing interval for chronic treatment
• Predictive biomarkers for treatment response (OCT features being explored)
• Comparison with complement inhibitors approved for geographic atrophy
• Combination therapy with anti-VEGF agents for wet AMD or DME
• Efficacy in different stages of dry AMD (early vs. intermediate vs. advanced)

Addressing these research gaps will be important for establishing a more complete understanding of Risuteganib's therapeutic potential and safety profile.

Related Reading#

• Risuteganib overview and research guide
• Risuteganib dosing protocols
• Risuteganib molecular structure